Morningstar

Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View

Provided by Dow Jones

By Rob Curran 




  Danaher's third-quarter net income and sales rose sharply and the maker of laboratory equipment boosted its adjusted earnings growth projection for the year. 



  The Washington, DC, life-sciences, biotechnology and diagnostics company posted earnings of $1.24 billion, or $1.75 a share, for the quarter ended Sept. 25, up from $908 million, or $1.27 a share, a year earlier. 



  Stripping out certain one-off items, adjusted earnings amounted to $2.11 a share, higher than the mean Wall Street estimate of $1.91 a share, according to a poll on FactSet. 



  Revenue rose 8.3% to $6.55 billion, just shy of the average Wall Street projection of $6.56 billion. 



  For the fourth quarter, Danaher targeted growth in core revenue, excluding respiratory revenue, in a range between 4% and 5%. 



  For 2026, Danaher raised its projection for adjusted earnings to a range between $8.57 and $8.62 a share from a prior estimate of $8.45-to-$8.60 a share. 





  Write to Rob Curran at rob.curran@dowjones.com 





  (END) Dow Jones Newswires



  October 21, 2026 06:32 ET (10:32 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
Are TIPS ETFs the Best Way to Fight Inflation?
 
Plus, four TIPS ETFs with top marks from Morningstar, and what you need to know before investing. 
 
 
Daniel Sotiroff and Ivanna Hampton 
 
 
 
What’s Ahead for Stocks This Quarter—and Where to Invest
 
Morningstar’s chief market strategist and economist share their outlooks for the fourth quarter of 2026. 
 
 
David Sekera, CFA, Preston Caldwell, and Susan Dziubinski 
 
 
 
10 Best Blue-Chip Stocks to Buy for the Long Term
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
6 ETFs To Diversify Away From AI
 
A difficult problem has an easy solution. 
 
 
Daniel Sotiroff 
 
 
 
 

			Sponsor Center